Literature DB >> 17875684

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Hiroyuki Konishi1, Bedri Karakas, Abde M Abukhdeir, Josh Lauring, John P Gustin, Joseph P Garay, Yuko Konishi, Eike Gallmeier, Kurtis E Bachman, Ben Ho Park.   

Abstract

The oncogenic function of mutant ras in mammalian cells has been extensively investigated using multiple human and animal models. These systems include overexpression of exogenous mutant ras transgenes, conditionally expressed knock-in mouse models, and somatic cell knockout of mutant and wild-type ras genes in human cancer cell lines. However, phenotypic discrepancies between knock-in mice and transgenic mutant ras overexpression prompted us to evaluate the consequences of targeted knock-in of an oncogenic K-ras mutation in the nontumorigenic human breast epithelial cell line MCF-10A and hTERT-immortalized human mammary epithelial cells. Our results show several significant differences between mutant K-ras knock-in cells versus their transgene counterparts, including limited phosphorylation of the downstream molecules extracellular signal-regulated kinase and AKT, minor proliferative capacity in the absence of an exogenous growth factor, and the inability to form colonies in semisolid medium. Analysis of 16 cancer cell lines carrying mutant K-ras genes indicated that 50% of cancer cells harbor nonoverexpressed heterozygous K-ras mutations similar to the expression seen in our knock-in cell lines. Thus, this system serves as a new model for elucidating the oncogenic contribution of mutant K-ras as expressed in a large fraction of human cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875684     DOI: 10.1158/0008-5472.CAN-07-0108

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

2.  Basal but not luminal mammary epithelial cells require PI3K/mTOR signaling for Ras-driven overgrowth.

Authors:  Kristin A Plichta; Jessica L Mathers; Shelley A Gestl; Adam B Glick; Edward J Gunther
Journal:  Cancer Res       Date:  2012-09-24       Impact factor: 12.701

Review 3.  Omics and therapy - a basis for precision medicine.

Authors:  Joseph P Garay; Joe W Gray
Journal:  Mol Oncol       Date:  2012-03-08       Impact factor: 6.603

4.  KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.

Authors:  D P Modest; P Camaj; V Heinemann; B Schwarz; A Jung; R P Laubender; S Gamba; C Haertl; S Stintzing; S Primo; C J Bruns
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

5.  Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Authors:  Hiroyuki Konishi; Morassa Mohseni; Akina Tamaki; Joseph P Garay; Sarah Croessmann; Sivasundaram Karnan; Akinobu Ota; Hong Yuen Wong; Yuko Konishi; Bedri Karakas; Khola Tahir; Abde M Abukhdeir; John P Gustin; Justin Cidado; Grace M Wang; David Cosgrove; Rory Cochran; Danijela Jelovac; Michaela J Higgins; Sabrina Arena; Lauren Hawkins; Josh Lauring; Amy L Gross; Christopher M Heaphy; Yositaka Hosokawa; Edward Gabrielson; Alan K Meeker; Kala Visvanathan; Pedram Argani; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

Review 6.  PI3K and STAT3: a new alliance.

Authors:  Peter K Vogt; Jonathan Ross Hart
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

7.  PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.

Authors:  Michaela J Higgins; Julia A Beaver; Hong Yuen Wong; John P Gustin; Josh D Lauring; Joseph P Garay; Hiroyuki Konishi; Morassa Mohseni; Grace M Wang; Justin Cidado; Danijela Jelovac; David P Cosgrove; Akina Tamaki; Abde M Abukhdeir; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

8.  PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Authors:  Julia A Beaver; John P Gustin; Kyung H Yi; Anandita Rajpurohit; Matthew Thomas; Samuel F Gilbert; D Marc Rosen; Ben Ho Park; Josh Lauring
Journal:  Clin Cancer Res       Date:  2013-07-25       Impact factor: 12.531

9.  Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method.

Authors:  Marta Riera-Borrull; Esther Rodríguez-Gallego; Anna Hernández-Aguilera; Fedra Luciano; Rosa Ras; Elisabet Cuyàs; Jordi Camps; Antonio Segura-Carretero; Javier A Menendez; Jorge Joven; Salvador Fernández-Arroyo
Journal:  J Am Soc Mass Spectrom       Date:  2015-09-17       Impact factor: 3.109

10.  Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Authors:  Grace M Wang; Hong Yuen Wong; Hiroyuki Konishi; Brian G Blair; Abde M Abukhdeir; John P Gustin; D Marc Rosen; Samuel Ray Denmeade; Zeshaan Rasheed; William Matsui; Joseph P Garay; Morassa Mohseni; Michaela J Higgins; Justin Cidado; Danijela Jelovac; Sarah Croessmann; Rory L Cochran; Sivasundaram Karnan; Yuko Konishi; Akinobu Ota; Yoshitaka Hosokawa; Pedram Argani; Josh Lauring; Ben Ho Park
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.